Items tagged with Scientific research
WHO strongly supports global sharing of data from TB clinical trials to maximize learning and accelerate discoveries (post)
06 November 2018 | Geneva: To advance the development of new treatments against all forms of TB and maximize the impact of studies and trials undertaken in this area, WHO and partners have initiated a series of pioneering initiatives over the past few years. These are now bearing fruit.
Using freshly resected lung tissue from 21 patients and two distinct mouse models, tuberculosis researchers at the University of Alabama at Birmingham and the Africa Health Research Institute, or AHRI, have identified a protein that plays an essential role in host defense against this deadly disease.
New analysis of the structure and function of the naturally-occurring antimicrobial agent tunicamycin has revealed ways to produce new, safe antibiotics for Mycobacterium tuberculosis and other disease-causing bacteria.
In a new study published in the Journal of Experimental Medicine, scientists at the University of Notre Dame have discovered that the pathogen Mycobacterium tuberculosis (MTB) releases RNA into infected cells. This RNA stimulates the production of a compound known as interferon beta that appears to support the growth of the pathogen.
TB in the blood (post)
Although a quarter of the world population is infected with the pathogen that causes tuberculosis, only about ten percent develop the disease during their lifetime. An international team of scientists, including some from the Max Planck Institute for Infection Biology in Berlin showed that the amounts of certain chemical compounds which circulate in the blood, change prior to the onset of the disease even months before a clinical diagnosis can be made. In the future, this may allow to predict tuberculosis based on a blood screening – a highly valuable progress in the fight against this life threatening disease.
Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments
If you live in the United States, you are unlikely to come into contact with the microbe that causes tuberculosis. Your odds of encountering the microbe are so low, in fact, that risk factors for the disease can easily go unnoticed: If you happened to carry a gene that predisposed you to tuberculosis, you likely wouldn’t know.
STAT will host a webinar on 22 January 2019 on the future of clinical trials.
Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up and mass-produced for clinical testing.
Tuberculosis (TB) is one of the leading causes of death from infectious diseases. Globally, it accounts for around 1.3 million deaths and 10.4 million people develop the disease every year.
Page 36 of 40 · Total posts: 0←First 35 36 37 Last→